CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Menu
Begin main content
Home About CADTH What We Do Programs and Services CADTH Reimbursement Review romosozumab
Back to Programs and Services

CADTH Reimbursement Review

romosozumab

Last Updated: January 4, 2021
Result type: Reports
Project Number: SR0676-000
Product Line: Reimbursement Review

Generic Name: romosozumab

Brand Name: Evenity

Manufacturer: Amgen Canada Inc.

Therapeutic Area: Osteoporosis, postmenopausal women

Indications: The treatment of osteoporosis in postmenopausal women at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture.

Manufacturer Requested Reimbursement Criteria1: The treatment of osteoporosis in postmenopausal women with a history of osteoporotic fracture and who are at very high risk for future fracture.

Submission Type: Initial

Project Status: Pending

Call for patient/clinician input open: January 4, 2021

Call for patient/clinician input closed: February 26, 2021

Anticipated Date: February 1, 2021

Fee Schedule: Pending

  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
Submit Feedback